Month: June 2022

American children under age 5 could receive their first COVID-19 vaccines as early as June 21, the White House’s top COVID official said Thursday — if the two vaccines under review are approved by both U.S. government bodies responsible for such authorizations.

“We know that many, many parents are eager to vaccinate their youngest kids,” said White House Coronavirus Response Coordinator Dr. Ashish Jha. “And it’s important to do this right. And that’s what this process has been all about.”Starting Friday, he said, the federal government will make 10 million doses available for order by states, pharmacies, community health centers and federal entities. Once the Food and Drug Administration approves the vaccine, those doses can be shipped, and once the Centers for Disease Control and Prevention gives its approval, children can start to get vaccinated. He predicted that if the process unfolds smoothly, children could begin receiving shots on June 21.

Currently, only children 5 or older are eligible for two-dose vaccines and for booster shots. If the vaccine is approved, the doses will be smaller than adult doses, Jha said, and the government has encouraged suppliers to make vaccinations available outside work and school hours, so parents can easily access them.

“We are prepared,” said White House press secretary Karine Jean-Pierre. “We’re working with states, local health departments, pediatricians, family doctors, other health providers and pharmacies to get ready, as we did with kids that are between 5 and 11. So we want to make sure that we get this done swiftly but also safely and … follow CDC recommendations.”

Last month, during the Quad leaders summit in Tokyo, the U.S. committed to providing COVID-19 boosters and pediatric doses to countries in greatest need, including in the Indo-Pacific. But it’s not clear whether the administration has firm plans to donate the vaccines for young children at this point.

“One of the things that the Quad partners are committed to is making sure that doses are safe and effective, and not trying to do anything to try and prejudge the approval process,” a senior administration official told VOA.

Moderna asked for authorization for pediatric vaccines in late April; Pfizer asked last month. The most recent survey from the Kaiser Family Foundation found that 18% of parents of under-5 children will get their children vaccinated quickly. But 38% say they will wait and observe how others take the vaccine. And another 38% say they will either “definitely not” pursue the vaccine or will do so only if required.

Johns Hopkins University, a leading tracker of the pandemic, notes that parental uptake of child vaccinations has been “stubbornly slow,” with less than 30% of children receiving the vaccine.

“The consistent message throughout the pandemic has been that the virus is mild for children,” said Rupali Limaye, deputy director of the International Vaccine Access Center.

The CDC emphasizes that the child-sized vaccine is safe and effective.

While severe cases among children are less prevalent than among adults, the CDC notes that since the pandemic began, COVID-19 has taken the lives of 479 American children under age 5.

Source: Voice of America

As China’s COVID-containment lockdowns stall goods en route to price-conscious U.S. consumers, New Jersey manufacturer Mitch Cahn is finding traces of gold in the snapped links of the global supply chain.

Eleven miles from Manhattan, business is surging at Cahn’s textile company, which boasts a 100% local supply chain.

“We manufacture everything from scratch right here in north Newark. We have been in business for 30 years, we now have about 155 workers, and we are hoping to hire another 25 immediately,” said Cahn, founder and president of Unionwear.

Established in 1992, Unionwear manufactures customized baseball hats, scarves and backpacks in the North Ward of New Jersey’s most populous city.

“Business is very solid this year. We’ve seen a surge in business from companies that are no longer able to import goods, and now they are buying products domestically,” Cahn told VOA Mandarin.

For his customers, the “Made in USA” price is right after decades in which American stores were filled with less costly Chinese-made products.

His buyers are not alone in their support for U.S.-made goods. In a 2020 survey by the Reshoring Institute, which advocates the return of manufacturing to the U.S., about 70% of the American respondents said they preferred U.S.-made products. Among them, 83% said they would pay up to 20% more for products made domestically.

COVID snaps supply chain

China has imposed strict COVID-containment lockdowns that are disrupting the supply chain. Export goods are going nowhere as shipping companies increase freight charges and pandemic-related labor shortages worsen delays.

According to the BR Logistics website, container rates for China-U.S. routes are now between $15,000 and $18,000 dollars per 40-foot container, or two to three times higher than pre-pandemic prices.

In addition, the Ukraine crisis has disrupted the global energy supply, pushing oil prices, and therefore shipping costs, higher. Cahn’s baseball caps and other products gain an edge because his products travel shorter distances to reach U.S. buyers, a cost saving that helps counter China’s lower labor costs.

Cahn said that before the pandemic, his baseball caps cost about 30% to 40% more than imports from China.

Currently a baseball cap bought for $2.50 in China will end up being $8 to $9 dollars a unit when it gets to the U.S., he said, once tariffs, shipping costs, packaging and the cost of meeting testing requirements for goods manufactured overseas are added in. The 10% to 15% U.S. tariff imposed on textile products accounts for some of that price differential, according to just-style.com, an industry website.

On average, Unionwear’s baseball caps cost around $8 to $10 per unit wholesale.

“Now we are competitive,” Cahn said.

Now focused on supply chain resiliency because of the pandemic, companies bigger than his are seeing the benefits of using suppliers closer to their customers. “Many U.S. companies are realizing that keeping processes closer to home can be much more reliable and secure,” according to an April Thomasnet.com article.

General Motors announced on January 25 that it would invest $7 billion in its plant in the U.S. state of Michigan to advance production of electric and autonomous vehicles through 2025, according to a news release from the Michigan Economic Development Corporation.

Although the announcement made no mention of China, it said the investment would solidify and strengthen the supply chain throughout Michigan, long known for its concentration of automotive-related manufacturers and suppliers. As Governor Gretchen Whitmer boasted, it’s “the place that put the world on wheels.”

Some non-U.S. companies have also pledged to invest in the U.S. to serve their customers in the North American market. South Korea’s Samsung announced in November that it would invest $17 billion in a new facility in Texas to produce advanced semiconductors and ensure the “stability of the global semiconductor supply chain.” The plant is expected to become operational in late 2024.

Samsung, which has operated a memory chip plant in China since 2014, is part of a larger trend. According to the most recent Kearney Reshoring Index released in 2022, “79 percent of executives who have manufacturing operations in China have either already moved part of their operations to the United States or plan to do so in the next three years, and another 15 percent are evaluating similar moves.”

‘Triple bottom-line mindset’

William Reinsch, an expert in international trade at the Center for Strategic and International Studies, a Washington think tank, said that many U.S. companies have been considering localizing their supply chains for quite some time.

“This is not a new thing. This is at least [a] 10-year trend. [The companies] want to have shorter supply chains. They want to be near their customers. They are concerned about volatile energy prices and rising shipping costs, both ocean freight and air freight,” he told VOA Mandarin.

The tariffs imposed during the Trump administration on most Chinese imports have created price spikes that have made it more expensive to import those goods, Reinsch said, and COVID-19 has revealed supply chain flaws to companies.

Harry Moser is the founder and president of the Reshoring Initiative, a nonprofit group focused on bringing manufacturing back to the U.S. Moser told VOA Mandarin that “20% to 30% of the companies can be brought back without raising prices to their customers, without reducing their profit margin, by recognizing all the costs that they previously ignored.”

Some examples of products ripe for reshoring, Moser said, include those that incur high freight charges or involve frequent design changes, or those with volatile demand, such as seasonal clothing.

“The idea here would be to shorten supply chains,” said Nick Vyas, an associate professor of operations and a supply chain expert at the University of Southern California Marshall School of Business.

The customer-centric supply chain would benefit companies in multiple ways, Vyas told VOA Mandarin. “It will be much more resilient, and it certainly would be a lot more sustainable. We will have a lot less carbon footprint than what we have produced over the last 30 years.”

Vyas said that for the past three decades, business leaders ran companies with a bottom-line mindset that considered only the cost of manufacturing.

“We need to get into the triple bottom-line mindset: Cost is one variable, but we also need to think about resiliency and sustainability,” he said.

Unionwear’s Cahn is optimistic about reshoring. He thinks the era of cheap imports is over and has some advice for companies looking to strengthen their supply chains: “I think it makes sense to develop a relationship with domestic source of supply … and also develop relationships with suppliers” in places such as the Caribbean Basin, South America and Canada. With tighter links, manufacturers can “insulate [themselves] from the ever-increasing costs of getting goods across the oceans.”

Source: Voice of America

– Tropical storms and cyclones have killed at least 214 people and affected more than half a million in Madagascar this season, the United Nations said Tuesday.

“Six tropical weather systems hit Madagascar from January to April 2022, killing at least 214 people and affecting about 571,100 across the country,” the humanitarian agency OCHA said.

One of the poorest nations in the world, Madagascar is prone to numerous storms and cyclones between November and April every year.

It was battered by one storm after another this year.

Tropical Storm Ana struck in late January, killing 55 people.

Another storm, Cyclone Batsirai, struck the island on February 5, claiming 121 lives. Cyclone Emnati then again hit the east coast, killing another 15.

Between both, Tropical Storm Dumako lashed the northeast in mid-February, killing 14 people in floods.

Cyclone Gombe in early March did not cause great damage, but Tropical Storm Jasmine late the following month killed five people.

Madagascar‘s southern region has also been ravaged by drought, leading to malnutrition and pockets of famine.

“By the end of February, more than 61 percent of the Grand Sud’s territory remained affected by extreme or emergency drought,” OCHA said, citing the UN children’s agency UNICEF.

Thanks to humanitarian assistance, “food insecurity and malnutrition in the Grand Sud improved in the first quarter of 2022,” it added. But the situation remained fragile, with seven of 10 districts still in crisis.

Source: Seychelles News Agency

Luanda – The Angolan National Football Team have made an auspicious start to the qualifiers for the 2023 African Nations Cup, in Côte d’Ivoire, after beating CAR, 2-1, Wednesday, in a match played at the 11 de Novembro stadium, in Luanda.

The match is for the first round of group (E).

Source: Angola Press News Agency

As health authorities in Europe and elsewhere roll out vaccines and drugs to stamp out the biggest monkeypox outbreak beyond Africa, some doctors acknowledge an ugly reality: The resources to slow the disease’s spread have long been available, just not to the Africans who have dealt with it for decades.

Countries including Britain, Spain, Portugal, Italy, Switzerland, the United States, Israel and Australia have reported more than 500 monkeypox cases, many apparently tied to sexual activity at two recent raves in Europe. No deaths have been reported.

Authorities in numerous European countries and the U.S. are offering to immunize people and considering the use of antivirals. On Thursday, the World Health Organization will convene a special meeting to discuss monkeypox research priorities and related issues.

Meanwhile, the African continent has reported about three times as many cases this year.

There have been more than 1,400 monkeypox cases and 63 deaths in four countries where the disease is endemic — Cameroon, Central African Republic, Congo and Nigeria — according to the Africa Centers for Disease Control and Prevention. So far, sequencing has not yet shown any direct link to the outbreak outside Africa, health officials say.

Monkeypox is in the same family of viruses as smallpox, and smallpox vaccines are estimated to be about 85% effective against monkeypox, according to WHO.

Since identifying cases earlier this month, Britain has vaccinated more than 1,000 people at risk of contracting the virus and bought 20,000 more doses. European Union officials are in talks to buy more smallpox vaccine from Bavarian Nordic, the maker of the only such vaccine licensed in Europe.

U.S. government officials have released about 700 doses of vaccine to states where cases were reported.

Such measures aren’t routinely employed in Africa.

Dr. Adesola Yinka-Ogunleye, who leads Nigeria’s monkeypox working group, said there are currently no vaccines or antivirals being used against monkeypox in her country. People suspected of having monkeypox are isolated and treated conservatively, while their contacts are monitored, she said.

Generally, Africa has only had “small stockpiles” of smallpox vaccine to offer health workers when monkeypox outbreaks happen, said Ahmed Ogwell, acting director of the Africa CDC.

Limited vaccine supply and competing health priorities have meant that immunization against monkeypox hasn’t been widely pursued in Africa, said Dr. Jimmy Whitworth, a professor of international public health at the London School of Hygiene and Tropical Medicine.

“It’s a bit uncomfortable that we have a different attitude to the kinds of resources we deploy depending on where cases are,” he said. “It exposes a moral failing when those interventions aren’t available for the millions of people in Africa who need them.”

WHO has 31 million doses of smallpox vaccines, mostly kept in donor countries and intended as a rapid response to any re-emergence of the disease, which was declared eradicated in 1980.

Doses from the U.N. health agency’s stockpile have never been released for any monkeypox outbreaks in central or western Africa.

Dr. Mike Ryan, WHO’s emergencies chief, said the agency was considering allowing rich countries to use the smallpox vaccines to try to limit the spread of monkeypox. WHO manages similar mechanisms to help poor countries get vaccines for diseases like yellow fever and meningitis, but such efforts have not been previously used for countries that can otherwise afford shots.

Oyewale Tomori, a Nigerian virologist who sits on several WHO advisory boards, said releasing smallpox vaccines from the agency’s stockpile to stop monkeypox from becoming endemic in richer countries might be warranted, but he noted a discrepancy in WHO’s strategy.

“A similar approach should have been adopted a long time ago to deal with the situation in Africa,” he said. “This is another example of where some countries are more equal than others.”

Some doctors pointed out that stalled efforts to understand monkeypox were now complicating efforts to treat patients. Most people experience symptoms including fever, chills and fatigue. But those with more serious disease often develop a rash on their face or hands that spreads elsewhere.

Dr. Hugh Adler and colleagues recently published a paper suggesting the antiviral drug tecovirimat could help fight monkeypox. The drug, approved in the U.S. to treat smallpox, was used in seven people infected with monkeypox in the U.K. from 2018 to 2021, but more details are needed for regulatory approval.

“If we had thought about getting this data before, we wouldn’t be in this situation now where we have a potential treatment without enough evidence,” said Adler, a research fellow at the Liverpool School of Tropical Medicine.

Many diseases only attracted significant money after infecting people from rich countries, he noted.

For example, it was only after the catastrophic Ebola outbreak in West Africa in 2014-2016 — when several Americans were sickened by the disease among the more than 28,000 cases in Africa — that authorities finally sped up the research and protocols to license an Ebola vaccine, capping a decades-long effort.

At a press briefing on Wednesday, WHO’s Ryan said the agency was worried about the continued spread of monkeypox in rich countries and was evaluating how it could help stem the disease’s transmission there.

“I certainly didn’t hear that same level of concern over the last five or 10 years,” he said, referring to the repeated epidemics of monkeypox in Africa, when thousands of people in the continent’s central and western parts were sickened by the disease.

Jay Chudi, a development expert who lives in the Nigerian state of Enugu, which has reported monkeypox cases since 2017, hopes the increased attention might finally help address the problem. But he nevertheless lamented that it took infections in rich countries for it to seem possible.

“You would think the new cases are deadlier and more dangerous than what we have in Africa,” he said. “We are now seeing it can end once and for all, but because it is no longer just in Africa. It’s now everybody is worried.”

Source: Voice of America

A jury on Wednesday ruled in favor of Johnny Depp in his libel lawsuit against ex-wife Amber Heard, vindicating his stance that Heard fabricated claims that she was abused by Depp before and during their brief marriage.

The jury also found in favor of Heard, who said she was defamed by Depp’s lawyer when he called her abuse allegations a hoax.

Jury members found Depp should be awarded $10.35 million in damages, while Heard should receive $2 million.

The verdicts bring an end to a televised trial that Depp had hoped would help restore his reputation, though it turned into a spectacle of a vicious marriage. Throughout the trial, fans — overwhelmingly on Depp’s side — lined up overnight for coveted courtroom seats. Spectators who couldn’t get in gathered on the street to cheer Depp and jeer Heard whenever either appeared outside.

Depp sued Heard for libel in Fairfax County Circuit Court over a December 2018 op-ed she wrote in The Washington Post describing herself as “a public figure representing domestic abuse.” His lawyers said he was defamed by the article even though it never mentioned his name.

While the case was ostensibly about libel, most of the testimony focused on whether Heard had been physically and sexually abused, as she claimed. Heard enumerated more than a dozen alleged assaults, including a fight in Australia — where Depp was shooting a “Pirates of the Caribbean” sequel — in which Depp lost the tip of his middle finger, and Heard said she was sexually assaulted with a liquor bottle.

Depp said he never hit Heard and that she was the abuser, though Heard’s attorneys highlighted years-old text messages Depp sent apologizing to Heard for his behavior, as well as profane texts he sent to a friend in which Depp said he wanted to kill Heard and defile her dead body.

In some ways, the trial was a replay of a lawsuit Depp filed in Britain against a British tabloid after he was described as a “wife beater.” The judge in that case ruled in the newspaper’s favor after finding that Heard was telling the truth in her descriptions of abuse.

In the Virginia case, Depp had to prove not only that he never assaulted Heard, but that Heard’s article — which focused primarily on public policy related to domestic violence — defamed him. He also had to prove that Heard wrote the article with actual malice. And to claim damages he had to prove that her article caused damage to his reputation as opposed to any number of articles before and after Heard’s piece that detailed the allegations against him.

Depp, in his final testimony to the jury, said the trial gave him a chance to clear his name in a way the British trial never allowed.

“No matter what happens, I did get here, and I did tell the truth, and I have spoken up for what I’ve been carrying on my back, reluctantly, for six years.” Depp said.

Heard, on the other hand, said the trial has been an ordeal inflicted by an orchestrated smear campaign led by Depp.

“Johnny promised me — promised me — that he’d ruin my life, that he’d ruin my career. He’d take my life from me,” Heard said in her final testimony.

The case captivated millions through its gavel-to-gavel television coverage and impassioned followers on social media who dissected everything from the actors’ mannerisms to the possible symbolism of what they were wearing. Both performers emerge from the trial with reputations in tatters with unclear prospects for their careers.

Eric Rose, a crisis management and communications expert in Los Angeles, called the trial a “classic murder-suicide.”

“From a reputation management perspective, there can be no winners,” he said. “They’ve bloodied each other up. It becomes more difficult now for studios to hire either actor because you’re potentially alienating a large segment of your audience who may not like the fact that you have retained either Johnny or Amber for a specific project because feelings are so strong now.”

Depp, a three-time best actor Oscar nominee, had until recent years been a bankable star. His turn as Captain Jack Sparrow in the “Pirates of the Caribbean” film helped turn it into a global franchise, but he’s lost that role. (Heard’s and Depp’s teams each blame the other.) He was also replaced as the title character in the third “Fantastic Beasts” spin-off film, “The Crimes of Grindelwald.”

Despite testimony at the trial that he could be violent, abusive and out of control, Depp received a standing ovation Tuesday night in London after performing for about 40 minutes with Jeff Beck at the Royal Albert Hall. He has previously toured with Joe Perry and Alice Cooper as the group Hollywood Vampires.

Heard’s acting career has been more modest, and her only two upcoming roles are in a small film and the upcoming “Aquaman” sequel due out next year.

Depp’s lawyers fought to keep the case in Virginia, in part because state law provided some legal advantages compared with California, where the two reside. A judge ruled that Virginia was an acceptable forum for the case because The Washington Post’s printing presses and online servers are in the county.

Source: Voice of America